Michael Nofi sold $202K of Edgewise Therapeutics stock
By AlphaYouPublished Form 4
Nofi Michael
Reporting filer
Michael Nofi reported selling 4,442 shares of Edgewise Therapeutics, Inc. for about $202K ($45.43 a share on average). Form 4 filed Nov 10, 2026 lists 3 entries.
See the price move since this trade →
- Disclosed
- Nov 10, 2026
Reported details
3 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Nofi Michael | 2026-11-10 | M | Exercise or conversion | 10937.00 | 0.00 | 10,937 | 0 days | Filed terms
|
| Common Stock | Nofi Michael | 2026-11-10 | S | Sale | 4442.00 | 45.427 | 6,495 | 0 days | Filed terms
|
| Restricted Stock Units (derivative) | Nofi Michael | 2026-11-10 | M | Exercise or conversion | 10937.00 | 0.00 | 32,813 | 0 days | Filed terms
|
Common Stock
- Owner
- Nofi Michael
- Date
- 2026-11-10
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 10937.00
- Price
- 0.00
- Following holdings
- 10,937
- Reporting delay
- 0 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-10
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: false
- transaction Timeliness:
- transaction Shares: 10937.00
- transaction Price Per Share: 0.00
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 10937.00
- direct Or Indirect Ownership: D
Common Stock
- Owner
- Nofi Michael
- Date
- 2026-11-10
- Code
- S
- Action
- Sale
- Quantity
- 4442.00
- Price
- 45.427
- Following holdings
- 6,495
- Reporting delay
- 0 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-11-10
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: S
- equity Swap Involved: false
- transaction Timeliness:
- transaction Shares: 4442.00
- id: F1
- transaction Price Per Share: 45.427
- id: F2
- transaction Acquired Disposed Code: D
- shares Owned Following Transaction: 6495.00
- direct Or Indirect Ownership: D
Restricted Stock Units (derivative)
- Owner
- Nofi Michael
- Date
- 2026-11-10
- Code
- M
- Action
- Exercise or conversion
- Quantity
- 10937.00
- Price
- 0.00
- Following holdings
- 32,813
- Reporting delay
- 0 days
- Filed terms and references
Filed terms
- security Title: Restricted Stock Units
- conversion Or Exercise Price: 0.00
- transaction Date: 2026-11-10
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: M
- equity Swap Involved: false
- transaction Timeliness:
- transaction Shares: 10937.00
- transaction Price Per Share: 0.00
- transaction Acquired Disposed Code: D
- id: F3
- expiration Date: 2035-11-10
- underlying Security Title: Common Stock
- underlying Security Shares: 10937.00
- shares Owned Following Transaction: 32813.00
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Nofi Michael: Chief Financial Officer.
- F1: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
- F2: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $45.165 to $45.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on November 10, 2026.
Original sources
Prepared automatically from public filing data. Report a correction.